Ketoconazole foam - Stiefel Laboratories

Drug Profile

Ketoconazole foam - Stiefel Laboratories

Alternative Names: 2% Ketoconazole foam - Stiefel Laboratories; Extina

Latest Information Update: 31 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stiefel Laboratories
  • Class Antifungals; Azoles; Piperazines; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seborrhoeic dermatitis
  • Discontinued Mycoses

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 30 Aug 2011 First generic equivalent approved in the US for the topical treatment of seborrhoeic dermatitis in immunocompetent patients 12 years of age and older
  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top